SCHEMBL5020702

SCHEMBL5020702

O=C(CCCc1ccc(C(=O)NO)cc1)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 11/20 0.73
HDAC1 Q13547 13/20 0.71
NPC1 O15118 1/20 0.70
CASP3 P42574 1/20 0.70
RAB9A P51151 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
HDAC6 Q9UBN7 7/20 0.66
HDAC3 O15379 4/20 0.66
HDAC7 Q8WUI4 4/20 0.66
HDAC2 Q92769 4/20 0.66
HDAC10 Q969S8 3/20 0.66
HDAC4 P56524 2/20 0.66
HDAC11 Q96DB2 2/20 0.66
HDAC9 Q9UKV0 2/20 0.66
HDAC5 Q9UQL6 2/20 0.66
DPP4 P27487 1/20 0.56
CA12 O43570 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980194 0.90 HDAC1 (0.72) HDAC8HDAC1NPC1CASP3RAB9A
SCHEMBL1986357 0.85 HDAC1 (0.96) HDAC8HDAC1HDAC6HDAC3HDAC7
SCHEMBL1981700 0.85 HDAC8 (1.00) HDAC8HDAC1NPC1RAB9AHDAC6
SCHEMBL4580313 0.83 HDAC1 (1.00) HDAC8HDAC1HDAC6HDAC3HDAC7
SCHEMBL15522457 0.83 NPC1 (0.68) HDAC8HDAC1NPC1CASP3RAB9A
SCHEMBL839278 0.83 TDP1 (1.00) HDAC8HDAC1NPC1CASP3RAB9A
SCHEMBL12260634 0.82 TDP1 (0.77) HDAC8HDAC1NPC1CASP3RAB9A
SCHEMBL5020665 0.81 HDAC1 (1.00) HDAC8HDAC1HDAC6HDAC3HDAC7
SCHEMBL9774493 0.80 NPC1 (0.79) HDAC8HDAC1NPC1CASP3RAB9A
SCHEMBL10269837 0.80 TDP1 (0.79) HDAC8HDAC1NPC1CASP3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
WO-2008074132-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-26 WO disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC8 9/4885HDAC1 1/4885NPC1 787/4885
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC8 9/4885HDAC1 1/4885NPC1 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.